SLC5A2 and diabetic kidney disease: The available literature about the mechanistic aspects of the positive effects of SGLT2 inhibitors in early diabetic nephropathy is based on a relatively small number of studies in rats and mice supporting the idea that these compounds increase the solute concentration of fluid reaching the macula densa sustainably and activate TGF sustainably, reducing hyperfiltration and thereby preserving renal function.